By Dean Seal
CNS Pharmaceuticals said its Berubicin treatment for an aggressive and usually fatal brain cancer didn't show a statistically significant difference in overall survival during a clinical trial, leading to a selloff of its shares.
The biopharmaceutical company said Tuesday that superiority in overall survival had been the primary endpoint of the trial for Berubicin, though the treatment still shows a favorable safety profile. An analysis of the trial's outcomes is still ongoing, CNS said.
Shares fell 55% to $1.52 in premarket trading.
The trial was comparing Berubicin to Lomustine, which is the current standard of care in recurrent or progressive Glioblastoma Multiforme.
CNS said the trial data shows overall survival is comparable between the two treatments, including for patients with the most unfavorable tumor markers.
"We are awaiting long-term follow-up of patients still alive as well as those still on trial, and will evaluate our substantial clinical dataset to obtain additional insights," Chief Medical Officer Sandra Silberman said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 25, 2025 08:49 ET (12:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。